Cell and gene therapies (CGTs) are transforming not only the way in which we treat genetic and intractable diseases, but also the entire pharmaceutical ecosystem as we know it.

Suffice to say, the next generation of CGTs holds tremendous potential for therapeutic benefits. To realise this promise, however, stakeholders across the value chain – including but not limited to pharmaceutical companies, health care providers, health care payers, and patients – will need to come together to fundamentally recalibrate their commercial delivery modus operandi.

Central to this challenge is the high level of personalisation involved in the end-to-end production and delivery of CGTs, which means that current processes being deployed for traditional biopharma products cannot be easily adapted for use. Rather, what is needed is a multidisciplinary approach to designing a new operating model – one centred around complex, patient-centric journeys – and a holistic understanding of the stakeholder ecosystem.

Four imperatives for commercial delivery

Having played a role in the commercial launch of every single CGT product that has been approved to date, Deloitte has had a front-row seat to the global CGT sector's dynamic evolution over the last decade. In this report, we will discuss four imperatives for the commercial delivery of CGTs in Asia Pacific, distilled from our cumulative experience supporting CGT players in their go-to-market efforts both across the globe and within the region.

Deloitte’s five-step methodology to achieve commercial readiness for a CGT product

Deloitte’s experience has revealed that several common approaches can be deployed to help pharmaceutical companies orchestrate streamlined end-to-end commercial delivery processes for CGTs. Based on our experience, we have developed – and subsequently refined – a five-step methodology to move a CGT product from clinical to commercial readiness.